Saturday 17 October 2026
Export PACB’s income statement to Excel — free account
Pacific Biosciences of California, Inc.
PACB Healthcare Medical Devices
Pacific Biosciences of California, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $160.0 million, up 3.89% from fiscal 2024. In the quarter to June 2026, revenue fell 1.91%, EPS was flat, free cash flow fell 31.0% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.73
0.23
−11.73%
Follow PACB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.28 | 2.52 | 3.51 | 2.49 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(14.67) | (9.03) | (29.42) | (20.58) | |
P/B ratio |
0.00 | 170.60 | 104.86 | 10.67 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.83 | 4.83 | 5.79 | 4.73 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(7.87) | (6.91) | (8.33) | (5.96) | |
EV/FCF |
(11.55) | (10.86) | (7.79) | (5.56) | |
Quick Ratio |
3.90 | 4.67 | 4.32 | 5.21 | |
Current Ratio |
4.92 | 5.65 | 5.15 | 6.24 | |
Net Debt/EBITDA |
(10.11) | 60.22 | (9.89) | (9.78) | |
Debt/Assets |
85.70% | 0.00% | 82.31% | 80.33% | |
Debt/Equity |
(19.40) | 0.00 | 120.65 | 17.88 | |
Asset Turnover |
0.20 | 0.19 | 0.16 | 0.14 | |
Operating CF/Net income |
0.80 | 5.40 | 0.47 | 0.49 | |
Capex/Depreciation |
(0.84) | 11.12 | (0.21) | 0.02 | |
Interest Coverage |
(21.14) | (4.80) | (23.68) | (22.36) | |
Research and Development Expense of Revenue |
59.02% | 52.74% | 51.25% | 59.43% | |
Selling, General and Administrative Expense of Revenue |
85.61% | 83.79% | 76.27% | 80.90% | |
Intangible Assets out of Total Assets |
0.44 | 0.42 | 0.42 | 0.42 | |
Share Based Compensation of Revenue |
23.75% | 11.99% | 21.48% | 28.57% | |
Graham Net Nets |
(0.86) | (1.02) | (0.72) | (0.97) | |
Graham Number |
1.02 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(25.60%) | (32.58%) | (98.40%) | (132.81%) | |
Free Cash Flow Yield |
(15.42%) | (17.64%) | (21.20%) | (34.13%) | |
Revenue per Share |
0.13 | 0.12 | 0.15 | 0.13 | |
Operating CF per Share |
(0.11) | (0.15) | (0.06) | (0.06) | |
Capex per Share |
(0.01) | 0.14 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.13) | (0.01) | (0.07) | (0.06) | |
Cash per Share |
0.76 | 0.90 | 0.93 | 0.99 | |
Shareholders Equity per Share |
(0.11) | 0.01 | 0.02 | 0.12 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.11) | 0.01 | 0.02 | 0.12 | |
Free Cash Flow |
(39.19) | (2.73) | (19.93) | (18.62) | |
Working Capital |
269.83 | 304.16 | 302.22 | 331.03 | |
Capital Expenditures |
(3.61) | 41.96 | (0.86) | 0.09 | |
Net Current Asset Value |
(446.42) | (410.48) | (403.68) | (372.83) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.09 | (1.13) | 0.02 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
31.68 | 30.50 | 31.49 | 30.00 | |
Average Payables |
17.14 | 13.82 | 18.68 | 14.21 | |
Average Inventory |
57.46 | 52.51 | 54.02 | 59.45 | |
Average Assets |
788.66 | 821.58 | 1,022.27 | 1,126.61 | |
Average Common Equity |
14.14 | 47.00 | 255.97 | 244.61 |
Columns are period end dates